Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors? [electronic resource]
Producer: 20200826Description: e006019 p. digitalISSN:- 1941-7705
- Anticholesteremic Agents -- adverse effects
- Biomarkers -- blood
- Cardiovascular Diseases -- diagnosis
- Cost-Benefit Analysis
- Databases, Factual
- Drug Approval -- economics
- Drug Costs
- Dyslipidemias -- diagnosis
- Humans
- Lipids -- blood
- PCSK9 Inhibitors
- Practice Patterns, Physicians' -- economics
- Randomized Controlled Trials as Topic
- Risk Factors
- Serine Proteinase Inhibitors -- adverse effects
- Treatment Outcome
- United States -- epidemiology
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.